泰拉生物科学 TYRA

Todd Harris, Ph.D. has served as our President and Chief Executive Officer since November 2018 and as a member of our Board since August 2018. Prior to co-founding Tyra, Dr. Harris served in various roles, most recently as Head of Corporate Development at Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, from January 2016 to July 2018 and as a director thereof from April 2013 to December 2019, and previously as the founder and Chief Executive Officer of Sienna (then called Sienna Labs) from April 2013 to January 2016. In September 2019, Sienna Biopharmaceuticals filed for voluntary petition to allow restructuring under Chapter 11 of the United States Bankruptcy Code and ceased its operations in December 2019. Before Sienna, Dr. Harris was a consultant at McKinsey & Company in the Health Care Practice Division from September 2008 to December 2012. Dr. Harris holds a Bachelor of Science Degree in Electrical Engineering from Brigham Young University, a Master of Science Degree in Bioengineering from the University of California, San Diego, and a Ph.D. in Medical Engineering and Medical Physics from Massachusetts Institute of Technology.

Bhavesh Ashar has served as our Chief Operating Officer since December 2025. Previously, he served as Chief Commercial Officer of SpringWorks Therapeutics, Inc. from March 2021 until September 2025, following its acquisition by Merck KGaA in July 2025. From May 2017 to March 2021, Mr. Ashar served as Senior Vice President, General Manager of U.S. Oncology for Bayer. Prior to that, Mr. Ashar served as Vice President, General Manager of U.S. Oncology for Sanofi Genzyme from May 2014 to April 2017 and as Vice President, Global Head of Transplant (Oncology Division) from December 2011 to April 2014, and earlier, held various roles of increasing responsibility at Sanofi Genzyme over an approximately 15-year tenure. Mr. Ashar received a Bachelor of Science degree in Mathematics from Imperial College in London and an MBA from the University of Chicago Booth School of Business.

Douglas Warner, M.D. has served as our Chief Medical Officer since September 2024. Dr. Warner served as Chief Medical Officer of eFFECTOR Therapeutics, Inc. from August 2022 until June 2024. Previously, Dr. Warner held roles of increasing responsibility over 18 years at Amgen Inc. where he oversaw extensive clinical development programs in multiple indications across oncology and general medicine. In his most recent position at Amgen, Executive Medical Director, Group Product Area Lead, Dr. Warner provided development guidance and oversight over a broad portfolio of solid tumor immune-oncology and pathway inhibitor development programs that ranged from Phase 1 to marketed products. Prior to this position, Dr. Warner was the Global Development Lead for several products including Vectibix, XGEVA, and Prolia. In this role, Dr. Warner led evidence generation and oversaw the design, execution, and analysis of studies across the phases of development, including large global Phase 3 trials, and was the clinical development leader for major regulatory filings worldwide. Dr. Warner is co-author on numerous peer-reviewed articles including those in The Lancet, The Lancet Oncology and The Journal of Clinical Oncology. He received his B.A. from the University of Pennsylvania, his M.D. from the Duke University School of Medicine, and his MBA from the UCLA Anderson School of Management.

Adele M. Gulfo, has served as a member of our Board since January 2025. She most recently served as the Chief Executive Officer, Biopharma Commercial, Sumitomo Pharma America, Inc. from July 2023 to October 2024, where she led the organization across a diverse portfolio spanning oncology, urology, rare disease, neurology and women's health. Previously, she served as Chief Commercial and Business Development Officer at Sumitovant Biopharma, Inc. (2020-2023) until its integration into Sumitomo Pharma. Prior to that she was Chief Commercial Development Officer at Roivant Sciences, where she played a key role in the formation of Sumitovant Biopharma and was instrumental in the launch preparations and commercialization of key brands, including ORGOVYX (prostate cancer), GEMTESA (overactive bladder), RETHYMIC (congenital athymia), and MYFEMBREE (women's health). Prior to Roivant, Ms. Gulfo held several senior leadership roles at Pfizer, including President and General Manager of the company's U.S. Primary Care Business Unit, President of Latin America, and Country Manager for its U.S. Biopharma Business, where she oversaw Market Access and Commercial Operations across the Primary Care, Specialty and Oncology divisions. Earlier in her career at Pfizer, she was instrumental in the development, launch, and commercialization of LIPITOR. Before joining Pfizer, Ms. Gulfo held multiple Vice President positions at AstraZeneca, including Commercial Readiness, Business Development and the Cardiovascular Business Unit, where she led the launch and commercialization of CRESTOR. Ms. Gulfo currently serves as a member of the board of directors of New Amsterdam Pharma Co N.V. and Enpro Inc., and previously served on the boards of directors of Myovant Sciences, Bemis Company, Inc. (acquired by Amcor plc) and Medexus Pharmaceuticals Inc. She also currently serves on the board of Battelle, an applied science and technology organization, and on the Innovation Growth Board for Mass General Brigham. Ms. Gulfo holds a Bachelor of Science in Biology from Seton Hall University and an MBA in Marketing from Fairleigh Dickinson University.

Robert More has served as a member of our Board since November 2018 and our Chairman since March 2019. Since November 2016, Mr. More has served as Managing Director of Alta Partners, a venture capital firm. From July 2013 to May 2015, Mr. More served as Senior Advisor for the Bill and Melinda Gates Foundation and led its Global Health Venture Initiative. He served as a General Partner of venture capital firms Frazier Healthcare Ventures and Domain Associates from September 2008 to June 2013 and from June 1996 to July 2008, respectively. Mr. More currently serves on the board of directors of Vir Biotechnology, Inc, a publicly traded company, and is a member of its audit committee and serves as Chair of its compensation committee. He also currently serves on the boards of directors of the following privately held biotechnology companies: Amplitude Therapeutics; eGenesis Bio; Kelonia Therapeutics; MBrace Therapeutics; SciThera; and Variant Bio, Inc. Mr. More was a founding member of the board of directors of the Kauffman Fellows Program and previously served on the board of directors of One Revolution and The Foundation for Innovative New Diagnostics. He received his Bachelor of Science Degree in Biology from Middlebury College and an MBA from the Darden School of Business Administration at the University of Virginia.

Rehan Verjee has served as a member of our Board since June 2021. Mr. Verjee is currently the founding CEO of Precede Biosciences, a venture-backed, liquid-biopsy diagnostic and data company. Prior to founding Precede Biosciences, Mr. Verjee was a member of the Healthcare Executive Committee of Merck KGaA from October 2015 to March 2021. During this time, Mr. Verjee served as the President of EMD Serono and as the Chief Marketing and Strategy Officer for the Healthcare business of Merck KGaA. As the President of EMD Serono, Mr. Verjee led a significant enterprise through a period of transformation and growth that included the FDA approval and launch of four new medicines, including two medicines in oncology. As the Chief Marketing and Strategy Officer of Merck's Healthcare business, Mr. Verjee was accountable for product and portfolio strategy across all specialty medicine therapeutic areas (oncology, neurology, immunology and infertility), a role that included co-chairing the R&D development committee (responsible for all R&D decisions from Phase 1 to approval), leading global business development (including delivering on a deal for a promising immunotherapy), chairing significant global R&D alliances, and having responsibility for the launches of new medicines across the major markets including the USA, the EU, China and Japan. Mr. Verjee is currently a member of the board of directors of the Massachusetts Biotechnology Council and of Precede Biosciences. Mr. Verjee holds a Master's Degree in Molecular and Cellular Biochemistry from the University of Oxford in the U.K.

Jake Simson, Ph.D. has served as a member of our Board since January 2020. Since December 2020, Dr. Simson has served as partner at RA Capital Management L.P., a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, and diagnostics. Previously, Dr. Simson served as an associate, analyst and principal at RA Capital Management from July 2013 to December 2020. Dr. Simson has served on the board of directors of Janux Therapeutics, Inc. since March 2021, Bicara Therapeutics Inc. since March 2023 and Septerna, Inc. since June 2023 and currently serves as a director for the following privately held companies: Convergent Therapeutics Inc., Outpace Bio, Inc., Parabilis Medicines, Inc., and Vivace Therapeutics, Inc. Dr. Simson holds his Bachelor of Science in Materials Science and Engineering from MIT and a Ph.D. in Biomedical Engineering from Johns Hopkins University. In his doctoral research he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels.

Susan Moran, M.D., M.S.C.E. has served as a member of our Board since May 2024. Dr. Moran served as Chief Medical Officer of RayzeBio, Inc. (acquired by Bristol Myers Squibb in February 2024) from July 2021 to May 2024. Prior to that, from March 2018 to June 2021, Dr. Moran was Chief Medical Officer at QED Therapeutics, Inc., an affiliate of BridgeBio Pharma, Inc., where she oversaw clinical development of infigratinib, leading to approval of Truseltiq. Prior to QED, Dr. Moran was at Puma Biotechnology, Inc. from 2014 to February 2018, contributing to the approval of Nerlynx. She was Senior Medical Director until December 2016 when her role expanded to Vice President and Head of Clinical Development. Dr. Moran has played roles in the development, registration, and post-marketing support of products for a number of solid tumors, including bile duct, urothelial, and liver cancer, among others, as well as multiple sclerosis, achondroplasia, and other disorders. She is a board-certified internist and has served on the faculty of the University of Pennsylvania School of Medicine and Harvard Medical School. Dr. Moran has served on the boards of directors of BioAtla, Inc. since December 2020 and Crescent Biopharma, Inc. since November 2024. Dr. Moran received her B.A. from the University of Virginia, M.D. from Duke University and M.S. in Clinical Epidemiology from the University of Pennsylvania School of Medicine.

S. Michael Rothenberg, M.D., Ph.D. has served as a member of our Board since May 2024. Dr. Rothenberg has served as Chief Medical Officer of insitro, inc. since February 2024. Prior to this, he held positions at Pfizer from March 2020 to January 2024, including Vice President and Head of Early Oncology Development and Clinical Research and Head of Early Clinical Development. Before his time at Pfizer, Dr. Rothenberg served in various roles at Loxo Oncology, Inc. from August 2015 to January 2020, including as Vice President of Research and Development and as Director of Research and Development. Prior to his work in biotechnology, he was a medical oncologist and cancer researcher at the Massachusetts General Hospital Cancer Center. Dr. Rothenberg received his B.A. in Chemistry from Yale University and earned his M.D. and Ph.D. from Stanford University.

On April 16, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the board of directors of Tyra Biosciences, Inc., and pursuant to the amended and restated bylaws of the Company, the Board approved an increase in the number of authorized directors from nine to ten and appointed Habib J. Dable to the Board as a Class II director with an initial term expiring at the Company's 2026 annual meeting of stockholders. Mr. Dable, 56, has served as an advisor at RA Capital Management, L.P., an investment manager, since April 2022. Previously, Mr. Dable served as President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company, from December 2016 until its acquisition by Merck in November 2021. Prior to joining Acceleron, Mr. Dable held roles of increasing responsibility at Bayer AG beginning in 1994, serving as the President of Pharmaceuticals for Bayer in the U.S. from October 2015 until December 2016. From 2013 to 2015, Mr. Dable served as the Executive Vice President and Global Head of Specialty Medicine for Bayer HealthCare Pharmaceuticals, and from 2010 to 2012, he was the Vice President of Ophthalmology & Global Launch Team Head for EYLEA. Mr. Dable has served as a member of the board of directors of Spyglass Pharma, Inc. since February 2026, Relay Therapeutics, Inc. since November 2025, Day One Biopharmaceuticals, Inc. since January 2024, and PepGen Inc. since September 2022, and he previously served as a member of the board of directors of Millendo Therapeutics, Inc. from September 2018 until January 2021, Blueprint Medicines Corporation (which was subsequently acquired by Sanofi S.A.) from June 2022 to July 2025, Aerovate Therapeutics, Inc. from July 2023 to April 2025, and Albireo Pharma, Inc. (which was subsequently acquired by Ipsen Biopharmaceuticals, Inc.) from August 2022 to March 2023. Mr. Dable holds a bachelor's degree in business administration and an MBA, each from the University of New Brunswick in Canada.

On April 1, 2026, the Board of Directors of Tyra Biosciences, Inc. designated Julia Rueb, Vice President, Finance of the Company, as the Company's principal accounting officer. Ms. Rueb has served as Vice President, Finance of the Company since January 2024. Previously, Ms. Rueb served as Director and Senior Director of Accounting and Corporate Controller from October 2022 to December 2023. From October 2021 to October 2022, Ms. Rueb served as Associate Director and Director, Technical Accounting at SOAProjects, Inc. From October 2020 to October 2021, Ms. Rueb served as a Manager at van den Boom & Associates LLC, where she provided accounting and finance consulting services to various companies, primarily in the life sciences industry, including the Company. Earlier in her career, Ms. Rueb was employed at Ernst & Young LLP from 2013 to October 2020, most recently serving as an Audit Manager, where she primarily served public life sciences companies. Ms. Rueb holds a Master's degree in Accounting from the University of San Diego and is a Certified Public Accountant. Ms. Rueb has no family relationships with any of the Company's directors or executive officers.

Effective as of April 1, 2026, Mr. Fuhrman continues to be the Company's principal financial officer. Alan Fuhrman has served as our Chief Financial Officer from January 2023 until the present. From December 2017 until his retirement in June 2020, Mr. Fuhrman served as Chief Financial Officer of Amplyx Pharmaceuticals, Inc. Prior to Amplyx, Mr. Fuhrman served as Chief Financial Officer of Mirna Therapeutics, Inc. from September 2015 to August 2017. Mr. Fuhrman also served as Chief Financial Officer of Ambit Biosciences Corporation from October 2010 to November 2014. Mr. Fuhrman served as a member of the board of directors of Checkmate Pharmaceuticals, Inc. from June 2019 until May 2022. Mr. Fuhrman also served as interim President and Chief Executive Officer of Checkmate Pharmaceuticals, Inc. from October 2021 through February of 2022. Mr. Fuhrman has been a member of the board of directors and chair of the audit committee of SpringWorks Therapeutics, Inc. since August 2019. Mr. Fuhrman has been a member of the board of directors of Esperion Therapeutics, Inc. since March 2020. Mr. Fuhrman also served as a member of the board of directors and chairman of the audit committee of Loxo Oncology, Inc. from January 2015 to February 2019. Mr. Fuhrman received B.S. degrees in business administration and agricultural economics from Montana State University and practiced as a CPA with Coopers and Lybrand.

Mr. Daniel Bensen was appointed as the Company's Chief Discovery Officer, effective as of December 1, 2025. Daniel Bensen has served as our Chief Operating Officer since November 2018 and previously also served as a member of our Board from November 2018 to January 2020. Prior to co-founding Tyra with Dr. Harris, Mr. Bensen served as Head of Immunology and Protein Chemistry at Cidara Therapeutics, Inc. from March 2014 until November 2018. Before Cidara, Mr. Bensen served as Principal Scientist, Protein Chemistry and Structural Biology at Trius Therapeutics, Inc. from March 2007 until February 2014. Mr. Bensen holds a Bachelor of Arts Degree in Biology from Point Loma Nazarene University in San Diego, California, and an MBA degree from the University of Southern California, Marshall School of Business.